1. Home
  2. RLTY vs IKT Comparison

RLTY vs IKT Comparison

Compare RLTY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest

RLTY

Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest

HOLD

Current Price

$13.80

Market Cap

262.5M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLTY
IKT
Founded
2022
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.5M
274.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RLTY
IKT
Price
$13.80
$1.63
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $5.55
AVG Volume (30 Days)
76.2K
★ 559.3K
Earning Date
01-01-0001
11-13-2026
Dividend Yield
★ 9.35%
N/A
EPS Growth
N/A
★ 57.76
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.34
$1.33
52 Week High
$16.41
$2.61

Technical Indicators

Market Signals
Indicator
RLTY
IKT
Relative Strength Index (RSI) 39.58 25.79
Support Level $13.34 $1.59
Resistance Level $15.92 $1.74
Average True Range (ATR) 0.22 0.11
MACD 0.06 -0.03
Stochastic Oscillator 61.06 4.85

Price Performance

Historical Comparison
RLTY
IKT

About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest

Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: